Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: Enigma, wrapped in mystery, enclosed in conundrum

Authors

  • Richard M. Ransohoff MD

    1. Neuroinflammation Research Center, Lerner Research Institute, Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH
    Search for more papers by this author

  • Potential conflict: Dr. Ransohoff has received fees for consulting with Biogenidec, the manufacturer of natalizumab.

No abstract is available for this article.

Ancillary